Cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival. Researchers report this at the ESMO 2014 Congress in Madrid. In Europe, about 70% of patients with cervical cancer are cured by either surgery or chemo-radiotherapy. Those patients with recurrent or secondary cancer have a very ...Monday, 29 September 2014
Adding Cediranib to Chemo Improves Progression-Free Survival of Recurrent Cervical Cancer
Cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival. Researchers report this at the ESMO 2014 Congress in Madrid. In Europe, about 70% of patients with cervical cancer are cured by either surgery or chemo-radiotherapy. Those patients with recurrent or secondary cancer have a very ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment